Answers are grounded in this paper and cite their sources.
This Web‐only perspective commentary discusses a new class of monoclonal antibodies that have garnered tremendous enthusiasm within the field of cancer immunotherapy, which has previously been hampered by complex, cumbersome agents and cells; individualized and laborious preparations; and questionable clinical efficacy.
No takes yet. Share an insight, caveat, or question.
Robert L. Ferris (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: